For the Inventor, By the Inventor

Enter assignee name

Barcelona, Spain

Almirall, S.a.

USPTO Granted Patents = 57

CIPO Patents = 71

EPO Patents = 60

Trademarks = 27

Forward Citations = 198

Loading Chart...

Loading Chart...

149 inventors (with patents filed for the assignee):

Maria Prat Quinones (16 out of 22 patents)

Carlos Puig Duran (16 out of 19 patents)

Maria Antonia Buil Albero (11 out of 23 patents)

4. Maria Dolors Fernandez Forner (10 out of 20 patents)

5. Jose Aiguade Bosch (8 out of 9 patents)

6. Silvia Gual Roig (7 out of 8 patents)

7. Silvia Fonquerna Pou (6 out of 11 patents)

8. Paul Robert Eastwood (6 out of 12 patents)

9. Jacob Gonzalez Rodriguez (5 out of 6 patents)

10. Maria Prat Quiñones (5 out of 13 patents)

11. Francesc Carrera Carrera (5 out of 5 patents)

12. Enrique Moyes Valls (5 out of 5 patents)

13. Gonzalo De Miquel Serra (4 out of 4 patents)

14. Joan Taltavull Moll (4 out of 5 patents)

15. Victor Giulio Matassa (4 out of 4 patents)

Core Competencies:

Pharmaceutical Compositions

JAK Inhibitors

Cyclohexylamine Derivatives

Quinuclidine Derivatives

Sodium Channel Inhibitors

P38 Mitogen-Activated Kinase Inhibitors

DHODH Inhibitors

Topical Formulations

Inhalation Devices

Aminoindazole Derivatives

Polymorphic Crystal Forms

Agonists of Beta-2 Adrenergic Receptor

57 patents: Sort by Forward Citations

1. 11602515 - Pharmaceutical compositions comprising dimethyl fumarate (2023-03-14),

2. 11000517 - Dosage and formulation (2021-05-11),

3. 10759793 - 2-(pyrazolopyridin-3-yl)pyrimidine derivatives as JAK inhibitors (2020-09-01),

4. 10588895 - Quinuclidine derivatives and medicinal compositions containing the same (2020-03-17),

5. 10456390 - Combinations comprising MABA compounds and corticosteroids (2019-10-29),

6. 10300072 - Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities (2019-05-28),

7. 10214509 - Amino-substituted heterocyclic derivatives as sodium channel inhibitors (2019-02-26),

8. 10173985 - Aminoindazole derivatives as sodium channel inhibitors (2019-01-08),

9. 10085974 - Dosage and formulation (2018-10-02),

10. 10034867 - Quinuclidine derivatives and medicinal compositions containing the same (2018-07-31),

11. 10005771 - Bicyclic derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities (2018-06-26),

12. 9907807 - Topical pharmaceutical compositions (2018-03-06),

13. 9757383 - Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities (2017-09-12),

14. 9737520 - Aclidinium for use in improving the quality of sleep in respiratory patients (2017-08-22),

15. 9687478 - Quinuclidine derivatives and medicinal compositions containing the same (2017-06-27),

Almirall, S.A. is a pharmaceutical company specializing in the research, development, manufacture, and sale of dermatological and aesthetic products. With a strong commitment to innovation, Almirall focuses on enhancing the health and well-being of individuals by providing effective solutions for skin conditions. Headquartered in Barcelona, Spain, Almirall operates globally, collaborating with healthcare professionals and patients to improve the quality of life for millions of people.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

57 Patents

#6 in Barcelona

#17 in Spain

#12,152 in the World

Barcelona, Spain

Almirall, S.a.

Forward Citations = 198

149 inventors:

Maria Prat Quinones (16 out of 22 patents)

Carlos Puig Duran (16 out of 19 patents)

Maria Antonia Buil Albero (11 out of 23 patents)

4. Maria Dolors Fernandez Forner (10 out of 20 patents)

5. Jose Aiguade Bosch (8 out of 9 patents)

Please report any incorrect information to support@idiyas.com

Loading…